Is promising tumour therapy possible in spite of unavoidable traditional medical interventions?

Martin Keymer, non-medical practitioner, Emsdetten

INTRODUCTION

The tumour diagnosis and tumour therapy system developed by me has been tested and has proven itself during the last seven years. It is definitely useful to demonstrate its possibilities and limits and to discuss our most important experiences and findings within the framework of this colloquium. As I made clear in my last two papers on this subjectl ‘ 2 , it was to be expected from the start that changes in the way one looks at things and changes in the therapy system would occur when practical experiences on a wide basis were available. This proved to be true. Here I wish to thank those of you who have helped not only by using this diagnosis and therapy system in your practice, but by reporting your experiences to me. Only this basic attitude of communication with each other and constructive criticism, but also of enthusiastic suggestions, enables us to understand more of the unbelievably functioning mechanism of the steady state called „man”, to counteract the growing therapy blockages in all areas and to find new ideas. And it is this communication and willingness to communicate which formed and continues to form the circle of BICOM® resonance therapists and why I personally was always willing to take on responsibilities within this study group.

BASIC RESEARCH

When I first came across this problem area in 1994, the term apoptosis3 was generally unknown. By contrast, the two genes which are mainly responsible, namely the MYC and p53 genes, presently form part of a whole series of experiments. However, these only progress slowly. Of course, from a classic traditional medical and scientific viewpoint it is unclear how the findings may be applied in practice except through invasive medicine, whose risks cannot be estimated. The position is quite different for us as BICOM® therapists!

The knowledge that we can in fact treat cancer patients successfully, is obtained mainly from two experiments done by the Dermatologisches Privatinstitut [Private Dermatologic Institute] from 1994 to 1996. The most important results are summarised in table 1.

In column 1 of table 1 there is a significant reduction in the weight of the tumour in the treated group. In column 2 this is expressed as a percentage. In column 4 a significant reduction in the number of metastases in the lungs may be seen, especially in the case of treatment with the „surrounding tissue Ai” ampoule. This is even clearer in column 5, where the percentage of mice with any kind of metastasis is given. Of course, this tendency is also reflected in the mitotic index listed in column 6.

A second experiment by Gabor Lednyiczki revealed that BICOM® resonance therapy influences structurally damaged genes. (Initially we did not really notice this.) This research on BICOM® resonance therapy was published as „Ober den EinfluB der BICOM®-Resonanz-Therapie auf die Regulation der zellularen StreBantwort im Tiermodell der Taufliege (Drosophila melanogaster)” [The influence of BIcom resonance therapy on the regulation of the cellular stress response in the animal model of the vinegar fly (Drosophila melanogaster)] (pp. 56 ff.). The Drosophila melanogaster larvae were exposed to a heat shock. Heat shock results in a serious change in proteins (they are lashed together) and in the production of so called heat shock proteins (HSDS). Untreated larvae were put in the input cup. Treatment type H was used, and the results clearly showed the positive influence which treatment with transmissions from healthy larvae had on larvae damaged by heat shock.

Therefore this experiment clearly shows that BICOM® resonance therapy is able to affect damaged genes.

This experiment already shows very positive results using the complete information from healthy Drosophila melanogaster flies in the input cup of the BICOM® instrument. Therefore we will exert an even greater influence on the irritation of p53 and MYC genes with a deliberate method such as the Cross-linked Test Technique using the isolated information from tumour tissue in combination with the MYC or p53 gene. This becomes comprehensible if, in accordance with our hypothesis, we regard a gene structure as an oscillator, a system capable of oscillating, rather than as fixed. If I cause this oscillator to resonate, it seems possible, due to the accurate information, that the repair mechanisms of the genes present in the cell can be activated.

Of course we have reached the first therapy limit of the MYC and p53 gene here. Should the MYC or p53 gene be absent, no resonance basis exists. It is also conceivable that a p53 or MYC gene structure is damaged excessively by radiation, mutation or something similar. This, however, cannot be postulated in advance. We must simply accept that a certain number of tumour patients cannot be helped even in this way.

THE FUTURE OF OUR THERAPY SYSTEM

During the last eighteen months I have been drawing further conclusions on gene therapy and the treatment of building proteins and receptors from these findings. Two years ago, within the framework of this colloquium, I gave some colleagues a prototype of different cell receptors containing the growth factor and the diabetes factor. Until now the results were disappointing, but I believe that I now know why this is so. In these prototype ampoules, isolated information is contained rather than a complex oscillatory spectrum. But obviously we need a complex oscillatory spectrum for the production of a resonance basis in order to cause the appropriate reactions. This I should have known sooner, since experience with the p53 or MYC gene in isolation shows that it only works in combination with the complete information of the tumour event. Furthermore, we know from the use of nosodes or the ampoules of the Cross-linked Test Technique that the isolated therapy of streptococcus with the pure streptococcus nosode, for instance, is much less effective than such treatment in combination with a fitting secretion, a lymph remedy and suitable stabilising ampoules. It is therefore necessary to cause the whole resonance basis to react in order to stimulate autohealing forces within the body.

In fact, this is also a reason why basic therapy with the patient in the input and output according to the rules of the Cross-linked Test Technique has never been neglected.

I am sure that I have already given you a taste of the topic of my paper at the colloquium of 2001. We are not far from discovering a quite new dimension to the diagnostic and therapeutic approach of BICOM® therapy. This will affect tumours, but also gene damage in general, the reconstruction of protein structures of the cytoskeleton, the regeneration of skin and connective tissue, as well as the stabilisation of the cell membrane and the receptors present on it. I regard this as extremely important for the future, since the following factors cause such an accumulation of attacking noxes on the cell membrane that I see one of the largest future problems here: increasing environmental pollution by aggressively toxic substances affecting the cell membrane in particular, the increasing overburdening of unspecific resistance mechanisms of the basic system according to Pischinger, in combination with toxic substance overload and the increasing radiation contamination caused by radioactivity, electrosmog, etc.

During the past 22 years I have been practising, I experienced several phases of how therapy systems had to change because of increasing therapy blockages. Looking back, they can be summarised as follows in the table of phases (see below).

It is therefore not strange that the BicOm instrument had to develop further to do justice to the different phases in order to be in step with our patients. BICOM® version 2000 with the BICOM® magnetic field and dynamic multi impulse bundles will definitely contribute to getting the fine resonances of our smallest oscillators, the proteins, going.

Here I wish to thank Dr Kreisl officially for his advice from the basis of his fundamental knowledge. I also wish to thank Dr StrothenIce, who plays an important role in encouraging me to think further in this direction.

PATIENTS THAT CANNOT BE TREATED SUCCESSFULLY

The above explanations, namely that the isolated information of a protein or gene receptor obviously does not result in satisfactory reactions, explains a second area where this therapy method does not achieve satisfactory reactions. This is the fact that, in the case of a far advanced and especially a highly degenerative tumour, as well as in the case of tumour mutations, the tumour cell itself casts off its cell receptors and therefore also the recognition receptors for the body. Mrs Nigmann, who has also been researching this therapy system from the start, always called this quite aptly the point of no return. The fact that a cell as a whole can no longer communicate, also means that the administered information via the corresponding tumour ampoule no longer finds a complex resonance basis and that this tumour therapy can no longer reach the cell.

At this point I wish to mention Mr Baklayan of Munich, who makes the decision (whether we are really dealing with a point of no return) easier with his brilliant „Kurzbak”. Otto von Bressensdorf from Aschheim near Munich showed us an excellent method for determining the status through analogue potentising. He does this by testing the „tumour A” and then the „surrounding tissue Ai” ampoule in all potency levels from the bottom to the top and from the top to the bottom. The patient is finished with treatment only when even D1000 shows nothing. Furthermore the found potencies are put in BRT oil and BRT minerals and prescribed as permanent medication.

Up to now I said that 30 % of all tumour patients do not respond to this treatment. Everyone who does tumour therapy must accept from thestart that he will have patients whom he cannot help. This means that he will have to deal with the death of his patients. He will have to counsel the dying. And he will have to take on the family of his patients, too. This requires a certain basic attitude and a fundamental decision from each of you before you attend a tumour seminar. You should avoid this subject and these seminars if you are unwilling to do this, if you do not have the necessary inner attitude, or if you do not want to deal with death.

I personally have no problem with a negative decision on your part. Because it requires a high input from oneself and it is certainly one of the most difficult tasks which we as holistic practitioners must face. I repeat, no test exists for the absence of the p53 or MYC gene, for such a serious mutation that repair is impossible, or for the point of no return. Patients at first seem to respond quite normally to the test ampoules and the therapy steps, and only after several weeks of treatment does one notice that a patient makes no progress at all. If this is the case, one must decide what should be done. This depends on the situation and the type of patient and how openly one can talk to him, or whether one can only talk to the family, or whether nothing should be said. There are no standard rules for this, in fact, it is a decision one must make quite alone.

However, if a patient cannot be saved, BICOM® therapy offers a fantastic possibility to make the patient’s life bearable. We all know that dying is an active process. However, one of the greatest problems of tumour therapy is the slow cachexia of the patient and his steadily declining vitality, which is finally reduced so far that that he cannot „start dying” and must expect a long and painful period of infirmity. General naturopathic measures and specific pain therapy with the BICOM® instrument can influence this life of suffering profoundly. It is fantastic that the patient’s remaining vitality can be mobilised with therapy type H in order to influence the final stages of the disease positively. I have always regarded it as one of the greatest successes of my naturopathic practice that the greater part of all patients who could not be saved could be prevented from enduring this painful infirmity. It was always possible for me to control the pain and it was also possible for the patient to die not in hospital, but within the family circle. Of this I have always been very proud.

PATIENTS THAT CAN BE TREATED SUCCESSFULLY

When I spoke before of about 30 % of all tumour patients who do not respond to tumour therapy, the opposite conclusion is that about 70 % of the patients definitely do respond very well to therapy. This success quotient lies far outside any known statistic, and it justifies the application of this therapy system to patients.

I will say it quite clearly in order to promote understanding: The activity of the p53 gene and the MYC gene is genetically fixed, i. e. this mechanism of cell suicide through the p53 gene and the inhibition of the p53 gene by the MYC gene is genetically fixed within each cell in our body and therefore present in each cell nucleus of each body cell. This is a law of life. The mechanism of the p53 and MYC genes is genetically fixed in order to cause too old, degenerated or damaged cells to die. Everyone has tumour cells in his body at each stage of life. They are degenerated, wrongly constructed or damaged cells. Wrong division even takes place while the embryo develops. The mechanisms of the p53 and MYC genes are present to enable the death of these cells and therefore the formation of new healthy cells at every stage in their life. This means that all old, damaged, wrongly divided, mutated, degenerated cells in our bodies die at any stage in their lives to create space for new life. This implies that the mechanism should be activated in the case of each tumour cell, since every tumour cell is a degenerated one. This means that the mechanism on which this tumour therapy is based is quite independent of the kind of tumour or of the tumour genesis. Colleagues always ask whether this therapy is also effective for a specific tumour. And my answer is always: „Yes!”, since we are speaking of a basic, genetically fixed law of nature. This can be clearly recognised from the fact that during both experiments either the MYC gene and the surrounding tissue from the human mamma carcinoma were put in the input cup or the p53 gene and additionally the human mamma carcinoma. However, the experiment itself was done with melanoma B16 in mice. The results listed above show that we truly deal with a law of life, since otherwise human mamma carcinoma in combination with the MYC or p53 gene would not affect a melanoma in mice.

BASIC PRINCIPLE: NO APOPTOSIS THERAPY WITHOUT A HOLISTIC TREATMENT APPROACH

I wish to make another fact quite clear. The tumour therapy developed by me aims to start the apoptosis process in the tumour patient in order to cause the death of the tumour cell. Nothing more! Just as the treatment of an allergen does not remove the main allergic susceptibility, the stimulation of apoptosis cannot influence tumour genesis or the background of a tumour disease. I want you to understand that the tumour therapy developed by me forms part of a holistically orientated tumour therapy within an all embracing therapy plan containing immune stimulating measures, measures for stabilising the metabolism, orthomolecular therapy, improvement of oxygen utilisation, of cell construction, psychotherapeutic measures and measures treating the true hidden individual causes which drove the body to develop a tumour.

The worst that a therapist can tell me one day is „and then I wiped out the tumour”. I believe that such a statement will cause me to turn in the grave.

I do not wish it to be understood that I want to cancel out the laws of biological cancer therapy. I see this therapy as an absolute complement to the therapeutic measures which Dr Reckeweg, Dr Issels, Dr Voll, Dr Schramm recorded and I can only confirm the statements by Dr von Braunschweig at the last colloquium4 . When you hear somebody say that I have said a tumour can simply be „beamed” away, or even if he only implies this, you can immediately assume this person has either never attended a tumour seminar presented by me, or that he was not in a position to understand what I said there. This is also the basic reason why I have given the strictest instructions that nobody may buy the degeneration test set unless he has attended my tumour seminar. I did this even though I have been greatly criticised and presented as autocratic and smug. I take the responsibility and I can tolerate these disparaging remarks about me.

A tumour patient should consistently follow the basic rules of the Therapeutic House. The fact that I demand this should no longer surprise you. If I demand that all patients follow the rules a hundred percent, a tumour patient should follow them two hundred percent.

As to diet, this means eating consistently sugarfree and vegan food, avoiding the primary food irritant (if this is a problem), as well as following the instructions for the treatment of fermentation or putrefaction dyspepsia.

Vegan food is also of crucial importance because I prescribe enzyme preparations in high dosages for every patient. I therefore use the proteolytic effect of the enzymes. This, however, only works when exclusively vegan food is eaten, since the administered proteolytic enzymes will otherwise primarily affect the proteins ingested as food. I call the following triad the „mesenchymal vacuum cleaner”: proteolytic enzymes; basic substances that mobilise acidic valences for deacidifying the basic system according to Pischinger (the basic substances must be taken in high enough dosages — use test strips to check the pH value of the urine — basic foods are not enough!); and rightspinning humine acids in high dosages (as contained for instance in In Vivo ZwischenzellgewebeAlctiv) for dissolving the primarily left spinning valences in the basic system according to Pischinger. In addition I prescribe individual cell building blocks (contained in In Vivo Zellbausteine Komplex) for building up the cell, since after the apoptotic process I must build up the healthy cell; cell membrane building blocks (contained in In Vivo Mucor javanicus) for building up the cell membrane; glutathione in high dosages (contained in In Vivo Glutathion Komplex, to be released soon); and additional orthomolecular substances in the appropriate individual dosages for building up unspecific resistance, like selenium, zinc, beta carotene, vitamin C.

The second pillar forming the basis of the Therapeutic House, namely drinking, requires drinking at least 2 to 2.5 litres of pure, revitalised water, also enriched with right spinning humine acids (AVS Liquidum). The third pillar demands BICOM optima®l skin function for excretion and the chain reaction between skin segment and organ area, which is only possible through allergy and paraffin free skin care. The fourth pillar, sleeping, demands appropriate sleep ergonomics as well as the presence of enough oxygen in the bedroom and observing the rules on geopathic and electrosmog pollution in the bed. The fifth pillar, enough exercise, requires discipline from the patient. The sixth pillar requires that you cause the patient to deal with thetumour psychically, and to do it with family members, too, to recognise that this is his problem and that he must conquer this tumour through his own inner attitude. This is especially true of psychosomatically induced tumours.

THE THERAPY SYSTEM

Therapy on a specific day involves stabilising the psychosomatic background burden, especially via the catalysts of the central control, then stabilising the chakra and treating the yin yang energy of the meridian on which the tumour lies (see table 2, point 1).

Thereafter the basic therapy follows, and consequently treatment with the patient’s own resonances (see table 2, point 2).

Then follows treatment of the tumour with the degeneration test set (see table 2, points 3 and 4).

Now previous traditional medical measures (see table 2, point 5) are taken into account. Should the patient’s own operation material be available, the corresponding therapy takes place (see table 2, point 6).

Tumour therapy without taking into account parasites, especially Fasciolopsis buslci, is unthinkable. This is explained at length at the tumour seminar, too (see table 2, point 7).

In conclusion, as is usual, stabilising measures are taken (see table 2, point 8).

From this you see that even in the daily therapy sessions the start of apoptosis is unthinkable without creating a corresponding consensus.

Additional measures are the consistent treatment of the individual hidden causes of the tumour genesis, according to the overall therapy plan as built up in the Cross linked Test Technique. (For this see my paper5 in RTI Heft 23. An exhaustive elaboration can be ordered from the Dermatologisches Privatinstitut [Private Dermatologic Institute].)

DISADVANTAGES OF ISOLATED BIOLOGICAL CANCER TREATMENT AND THE ADVANTAGES OF COMBINING BIOLOGICAL CANCER TREATMENT AND APOPTOSIS THERAPY

The greatest disadvantages of biological cancer therapy, which in principle has the goal to activate the patient’s own healing powers, are threefold:

1. The reasons why a tumour develops usually lies years or decades in the past. Usually there was a slow development of the tumour genesis, long term degeneration of the metabolism and increasing immune suppression. However, a tumour patient usually has very little energy and is in addition flooded with tumour toxins. General biological cancer therapy aims to activate the immune system, the metabolism, especially oxygen metabolism, the basic system according to Pischinger, the toxin excreting organs and therefore to cause the corresponding detoxification. But this takes time. However, during this time the tumour may develop further and counter the reversing therapy via the tumour toxins.

Advantage of activating apoptosis: One can deliberately intervene in the tumour situation from the first consultation. There are no prerequisites for the stimulation of apoptosis since it is a natural biological process. This means that I can intervene thoroughly in the tumour situation and simultaneously carry out the reversing therapy via biological tumour therapy.

2. A tumour patient who has neither been operated on nor treated with chemotherapy or radiotherapy when visiting your practice is a rarity. Operations may cause metastases. I will discuss this problem in detail later. However, in addition to the problems listed under 1, general biological cancer therapy must deal with massive and lasting immune suppression caused by chemotherapy and radiotherapy, the resultant radiation contamination in the case of radiotherapy and the toxic contamination in the case of chemotherapy. In other words, a patient who has already been treated with radiotherapy or chemotherapy reacts substantially worse to the reversing therapy. A therapy blockage should be postulated from the start. It must be removed before the measures of the reversing therapy will work. This also takes time.

Advantage of starting apoptosis: The fully burdened and blocked situation can be treated since apoptosis is a biological process and we mainly stimulate the p53 and MYC genes. If this gene structure is present, the oscillators can be treated even if the immune system, metabolism, excretion systems and biocybernetic regulatory systems are still blocked by radiotherapy or chemotherapy.

3. The patient usually receives traditional medical treatment while he comes to us for biological cancer therapy. This means that radiotherapy or chemotherapy may be done by the clinic concurrently with the biological tumour therapy. However, this is a true „sword of Damocles” for the biologically working therapist. He may assume that a new cycle of radiotherapy or chemotherapy will block any therapeutic measures anew. In principle he is degraded to accompanying the radiotherapy or chemotherapy, to compensating for their effects because the patient feels better and tolerates the treatment better and afterwards to neutralising the toxicity of these measures. From the beginning he knows that it destroys all his trouble, especially the reversing treatment, immune stimulation, stimulation of the metabolism.

But there is a further point. There are tumours where surgical or radiological measures are meaningful, namely those which are narrowly confined and clearly encapsulated. Furthermore, there are tumours which react positively to chemotherapy. They are listed in table 3.

It must be admitted that there are tumours where chemotherapy enables an extension of life (see table 4). But chemotherapy has no effect on a whole series of known tumours (see table 5).

This means that one must weigh up whether one should, as a responsible therapist, agree to surgery, radiotherapy or chemotherapy; yet one should not agree in the case of the tumours listed in table 5.

Something else should also be considered. We as therapists should not forget under what psychic pressure the patients are in their fear of death. And we should not underestimate the psychic terror usually wielded in hospital and by the tumour specialist when a patient does not agree to a medical procedure. This psychic terror does not only come from traditional doctors, but also from (fearful) family members and friends. In the case of psychically labile patients, agreement to the treatment of tumours listed in table 5 should be weighed up against the damage caused by psychic terror. The latter may cause greater damage.

But these therapeutic interventions are still fatal to the total regulatory situation.

Advantage of stimulating apoptosis: It is important to know that you can stimulate the process of apoptosis in this case, too. In other words, even during a course of radiotherapy or chemotherapy you can support these therapies by starting the process of apoptosis. Chemotherapy can be supported in its true effect via the chemo test set, as is explained in detail in the tumour seminar. You as therapist need no longer be afraid of possible chemotherapy or radiotherapy. You are not only doing supporting tumour therapy, but consistent apoptosis therapy.

RECOGNISING METASTASIS SITES

One of the extraordinary opportunities of the degeneration test set is the recognition of metastases as well as the early recognition of possible metastasis sites.

As can be seen in table 1, column 4 (the number of metastases in the lungs), only about 10 % of metastases are found in the case of therapy with the „surrounding tissue Ai” ampoule in comparison with the control group. As can be seen in column 5, the percentage of mice with general metastases is 17.8 ‘,/0 in contrast to 59.1 13/0.

This means that the inhibition of the MYC gene decreases metastases by more than 80 %. The logical conclusion is that the surrounding tissue of the metastasised cell allows growth at the metastasis site through inhibition of the p53 gene. When I noticed this fact, I immediately asked: „ Why is this?” Why does a healthy cell allow a degenerative cell to go on living though an active process (the activation of the MYC gene)?

I tried several different approaches. However, I finally found the solution after reading the work of Dr Hamer, who states that there is no tumour without a corresponding psychic background. Although I rigorously reject the therapeutic conclusions of Dr Hamer, I must admit that he is right in this instance. This conclusion immediately resulted in the combination of the degeneration test set with the catalysts of the central regulation. The test method is very simple:

If I wish to find a potential metastasis site, I put the „surrounding tissue H Di” ampoule in the input cup and test all meridians in the catalysts of the central control. The combination of „surrounding tissue H Di” and „large intestine KN 1″, for instance, shows me that a potential metastasis site is present in the large intestine, i. e. a readiness of the surrounding tissue to allow a possible metastatic cell to live.

If I want to know whether metastasis has occurred on a potential site, I simply need to switch the „surrounding tissue H Di” and „tumour A” ampoules, while the „large intestine KN 1″ ampoule remains. If I find the corresponding resonance, I have found a metastasis.

By using appropriate therapy measures it is therefore possible to stabilise potential metastasis sites even before metastasis takes place. It is also possible to treat the metastasis tumour in addition to the primary tumour even before the metastasis is large enough to be diagnosed by traditional medical means.

It is of elementary importance to find metastasis sites resulting from traditional medical treatment. I would search for metastasis sites before and after

• tumour surgery

• radiotherapy

• chemotherapy

because these therapy measures may release metastases which will form metastasis tumours. The exact method in such a case is discussed in detail at tumour seminars.

OUR DOMAIN: EARLY RECOGNITION OF CANCEROGENESIS

Obviously the degeneration test set is especially suitable for the early recognition of a tumour, since the „tumour A”, „tumour H Di”, „surrounding tis- sue Ai” and „surrounding tissue H Di” ampoules already test positively when the tumour degenera- tive process starts. Other ampoules are used to de- termine the degenerative tendency and even the degree of malignancy of the degenerative event. It is therefore possible not only to recognise the tu- mour, but also the aggressiveness of its growth tendency. A tumour can be recognised when it does not yet show by traditional means. When a tumour exists, the degree of its malignancy can be determined. As you know, some tumours are aggressive and others are characterised by slow growth. Depending on the results, you can individ- ualise the tumour treatment and decide whether to involve traditional medicine. In the case of a small, clearly delineated tumour, for instance, you may decide to do so for forensic reasons in order to clear up whether tumour surgery is a meaningful measure.

Of course you can proceed from the assump- tion that you will often be in the following situation: A patient comes to you because of other com- plaints, but because of the test results you suspect a possible tumour occurrence.. You test the corre- sponding ampoules, and the suspicion is confirm- ed immediately. Because the patient has received no radiotherapy or chemotherapy, he will react ex- tremely positively to treatment. I believe that the degeneration test set is the best early warning sys- tem for tumour occurrence available today.

CONCLUDING REMARKS

I hope that I have succeeded in demonstrating the present state of tumour diagnosis and tumour ther- apy in combination with Bicom technology. I have hopefully also succeeded in making clear that this tumour therapy should be applied in combination with other therapeutic measures. I also hope it is clear that, with these opportunities for tumour therapy, treatment combining traditional and biological therapy measures is sensible and right for certain tumours.

I would be happy to greet those of you who decide to deal responsibly with tumour patients at a tumour seminar. The next one is going to be held from 2 to 3 September 2000.

I recommend that you work with the degenera- tion test set for early recognition, even if you do not wish to get involved with this subject. You can then refer the patient to a tumour therapist in the region. The Institut flit’ Regulative Medizin or the Dermatologisches Privatinstitut [Private Derma- tologic Institute] will gladly refer you to someone near you, or you can look on the Internet.

Should you wish to obtain further information on tumour therapy, on the Cross-linked Test Tech- nique, on the Therapeutic House, on the over-all therapy plan, please visit our Internet homepage www.therapeutisches-haus.de.

Thank you for your attention.